MIBG scintiscans were performed in 353 patients with suspected pheochromocytomas. Extra-adrenal pheochromocytomas were identified in 15 of 18 patients who at operation were proven to have such tumors and normal adrenal glands. Conventional localization studies, often repeated, had failed to localize these tumors in nearly all Cases. Nine of the extraadrenal pheochromocytomas were found within the middle mediastinum. This group of unique tumors required further specialized localization studies with augmented computed tomography (CT) scans for specific anatomical delineation. These complementary studies allowed for precise planning of surgical excision of the tumors, which required cardiopulmonary bypass in some patients. Extraadrenal pheochromocytomas were identified in a family with no other endocrinopathies. The tumors in 3 patients from 3 different generations all were perirenal and involved the vena cava.
patients have had objective responses with diminution in size of metastases or primary malignant tumor and a decrease in the secretion of catecholamines.
This agent has been found to be of great value in detecting pheochromocytomas that often have defied all other means of localization. 131I MIBG concentrates in most malignant pheochromocytomas, and preliminary results suggest that it will be very useful in the trealment of this disease.
The diagnosis of pheochromocytoma is frequently simpler than the anatomical localization of the tumor. Elevations in plasma and/or urinary catecholamine and their metabolites, coupled with a characteristic clinical picture can usually establish the diagnosis. The tumor localization, however, particularly when there is malignant, extra-adrenal, or bilateral disease, may be very difficult. Approximately 10% of pheochromocytomas arise from chromaffin tissue anywhere from the base of the skull to the bladder. Furthermore, some pheochromocytomas may be multiple, in extra-adrenal locations, or concurrently intra-adrenal and extraadrenal. Third-generation computer assisted tomography is extremely accurate in localizing intra-adrenal lesions, but is not very helpful for identifying extra-adrenal or metastatic pheochromocytomas. Until recently, no available modality could provide both an anatomical and functional documentation of the tumor prior to surgical intervention. The synthesis of 131I meta-iodobenzylguanidine (131I MIBG) has made it possible to obtain scintigraphic images of pheochromocytomas and hyperplastic chromaffin tissue. This compound, a guanidine analogue with molecular structure similar to that of norepinephrine, was found by Wieland et al. [1] to have a strong affinity for adrenergic tissue. For the past 3 years, 13~I MIBG scintiscans have been used at The University of Michigan for the localization of pheochromocytomas and for screening patients with multiple endocrine neoplasia type II and other neuroectodermal dysplasias. 13~I MIBG has also been used in the management of inoperable and metastatic pheochromocytomas. This report describes our experience with this agent.
Methods and Materials

Patient Populations
During the 3-year period from August 1980, to August, 1983, a total of 353 patients with suspected pheochromocytomas was studied at The University of Michigan Medical Center. Nearly a third of the patients had the diagnosis established by biochemical studies. These patients were referred for localization and possible treatment of their pheochromocytomas. Many other patients had hypertension that was labile, difficult to control, or paroxysmal, and underwent scintiscans because to do so expedited their pheochromocytoma evaluation when they had been treated with a drug such as alphamethyldopa that interferes with biochemical testing. Some patients had suspicious but not diagnostic catecholamine elevations in either plasma or urine. Other patients with proven MEN IIa or Iib syndromes, without hypertension or biochemical evidence of pheochromocytoma, underwent scintiscans with 131I MIBG as part of a screening protocol. Although 131I MIBG scans were used primarily for localization, in a few cases the scan was the first diagnostic proof that a pheochromocytoma was present.
The 95 patients with proven pheochromocytomas ranged in age from 9 to 69 years. Fifty-one were males and 44 were females. With the exception of 2 MEN IIa patients who were asymptomatic except for episodes of palpitations and anxiety, all were hypertensive. There were 18 patients with familial disease associated with pheochromocytomas including 8 with MEN IIa, 3 with MEN IIb, 5 with neurofibromatosis, 1 with von HippelLindau, and 1 with Carney's triad (pheochromocytoma, gastric leiomyoblastoma, and pulmonary chondroma) [3] .
All patients with proven pheochromocytomas had at least 1 urinary catecholamine or catecholamine metabolite level within the diagnostic range. Many patients also had diagnostic elevations in their plasma catecholamines as well. In addition to undergoing the 1311 MIBG scan, patients were screened for pheochromocytoma by CT scanning.
Technique for Scanning with 1sli MIBG
131I MIBG was synthesized and prepared for intravenous injection as previously described [1, 2] . Lugol's iodine, 30 rag, was given orally for 5 days beginning 24 hours before the injection of ~3~I MIBG in order to block uptake of 1311 by the thyroid gland. A dose of 0.5 mCi per 1.7 m 2 of body surface area (not to exceed a total dose of 0.5 mCi) was injected intravenously over 10-20 seconds on the day prior to the first scan. Scanning was performed at 24, 48, and 72 hours after injection. In cases in which anatomic orientation was uncertain, (99mTc) pentetic acid or (99mTc) diethylene triaminepentacetic acid was also administered to visualize the kidney.
Administration of lsli MIBG for the Treatment of Metastatic or Inoperable Malignant Pheochromocytomas
Ten patients with unresectable metastases or inoperable primary tumors that showed uptake by 13JI MIBG scintography were administered therapeutic doses of this agent. Early in the experience with therapy, approximately 100 mCi was given as the initial dose. During the last year. however, patients have been given 200 mCi as a initial dose. The majority of patients have been given 2 or 3 doses with maximum of 600 mCi When administered therapeutically, 131I MIBG was given as a 100 mCi dose of 131I on 5 mg of MIBG and infused at the rate of 3 mg/30 min. intravenously. I1 was calculated that each dose of 100 mCi of MIBG would deliver approximately 3.400 rad. A therapeutic dose is now considered to be a total of 300 mCi or 10.200 rad delivered to the tumor.
Results
Isli MIBG Localization
Of 95 patients proven to have pheochromocytomas by operation or consistently diagnostic biochemical determinations. 85 were visualized by 131I MIBG scintigraphy (Table IL The false-negative rate was. therefore. 10.5%. There were no falsepositive studies. Eighteen of 19 patients with intraadrenal sporadic pheochromocytomas had localizing scintiscans. In the single false-negative case, a 51-year-old man had a large easily identifiable left adrenal pheochromocytoma that was cystic on CT scanning. The excised lesion was a fluid-filled neoplastic cyst with a maximum wall thickness of 0.5 cm. It is possible that cystic degeneration of Nine patients had pheochromocytomas found in the middle mediastinum. With 1 exception, all were initially discovered after 1311 MIBG scintiscanning. In 1 case. a tumor blush was initially seen as a result of coronary angiography. Three of these patients were males and 6 were females, ranging in age from 18 to 61 years. Five tumors were excised using cardiopulmonary bypass. In each of these. the left atrium was the site of origin of the tumor. Three of the 5 patients are considered cured. One patient died on the first postoperative day with diffuse intravascular coagulation. One patient has persistent disease because of skeletal metastases. One tumor was stripped from the atrium without the need for cardiopulmonary bypass and is cured. Another patient's tumor was in the aorticopulmonary window and could be excised without difficulty. One patient with Carney's syndrome has not undergone operation for p h e o c h r o m o c y t o m a because she has proven liver metastases with gastric leiomyoblastoma. Another patient is awaiting operation. These rare middle mediastinal pheochromocytomas have been reported in detail elsewhere [3] . Ten of 18 extra-adrenal pheochromocyt0mas proved to be malignant. There were 44 patients with malignant pheochromocytomas as determined by metastases in lymph nodes, liver, lung, or bone. In 18 of these, the primary tumor was extra-adrenal. In several cases the primary tumor was identified as malignant because metastases were discovered by the scintiscan (Fig. 2) . Malignant pheochromocytomas were identified by scintiscanning in 40 cases. Thirty-four of these were malignant sporadic pheochromocytomas. In addition, pheochromocyt0mas in 6 patients with familial disease were malignant. Two were MEN IIa patients and both had liver metastases that were visualized. Four additional patients had malignant pheochromocytomas that did not appear with MIBG scanning. In 3 of these cases the metastases were in bone and had been previously treated with external irradiation. In 1 patient, hepatic metastases did not appear although in several others they were easily identified.
In addition to the false-negative scan in I patient with an intra-adrenal pheochromocytoma, 3 patients, with surgically proven pheochromocytomas in the region of the right renal hilus, had negative 131I MIBG scans. Two of these pheochromocytomas were localized by CT scans. Selective aortography localized the third lesion. These 3 patients all had elevations of urinary catecholamine levels, diagnostic of pheochromocytoma. There were 4 patients with malignant disease whose metastases did not visualize. Two patients have persistently diagnostic levels O f catecholamines but these tumors have not as yet been localized by any study.
Therapeutic Use of 1311 MIBG
Thus far, 10 patients with metastatic pheochromocytomas or inoperable primary tumors have been treated with therapeutic doses of 131I MIBG. Five patients have shown objective responses as determined by decrease in tumor size to less than 50% of the original volume and/or significant decrease in urinary catecholamine levels. The most dramatic response has been seen in a 62-year-old male patient who had a large inoperable periaortic pheochromocytoma completely encircling his upper abdominal aorta and vena cava, extending from the diaphragm to the bifurcation of the aorta. This patient had severe pain radiating to his scrotum, severe hypertension, and intractable angina. During an attempted resection at another hospital, he had had a cardiac arrest and myocardial infarction. During a 2-year period (!980-1982), he was given 3 doses of 131I MIBG (500 mCi). His tumor size and urinary catecholamines have decreased to a third of pretreatment levels. In 1983 he underwent a successful triple coronary artery bypass without adrenergic blockage at another hospital. He has no hypertension.
Discussion
MIBG scintigraphy represents an important ad-
vance m the diagnosis and treatment of pheochromocytoma. Until now. adrenal lesions, if large enough, could be documented with computed tomography or anglography, but their functional status could not be readily assessed without selective plasma catecholamine sampling, which was often inaccurate. If a patient with the clinical and biochemical features of pheochromocytoma had an adrenal lesion on CT scan. it was presumed to be a pheochromocytoma. Preoperative assessment of metastatic involvement was difficult and frequently lesions in extra-adrenal sites were not visualized. In our series, the mean time interval from the diagnosis of pheochromocytoma to the diagnosis or identification of metastatic disease was 9 years (range 0-33 years). Among patients with a history of pheochromocytoma, the duration of symptoms due to metastases was 3.7 years (range 0-18 years) before identification by the 131I MIBG scintiscan.
Extra-adrenal metastatic lesions could be visualized in most cases. Until 131I MIBG became available. the discovery of an intra-thoracic pheochromocytoma was a rare and reportable event. Until 1980 only 24 cases of intra-thoracic pheochromocytomas were reported in the world literature [7] . In this series. 9 intra-pericardial lesions were identified by 131] MIBG scintiscanning. None was pro-spectively found by CT scanning, although one was suspected by the serendipitous appearance of a tumor blush during coronary angiography done for the evaluation of angina. It was further determined, once middle mediastinal lesions could be localized by 131I MIBG scintiscan, that augmented dynamic computer assisted tomography could precisely define the anatomical site of the lesion. As experience with 131I MIBG scanning increased, the usefulness of combined localization modalities became more apparent. Composite scanning techniques using technetium and other agents to identify kidneys, bone, and major blood vessels in conjunction with 131I MIBG have made preoperative localization even more accurate than previously achieved.
The specificity of this test as well as its sensitivity make it ideal for total body screening. Besides the adrenal medulla, uptake 3 hours after injection of 131I MIBG is significant only in the thyroid [1] . Blockage of iodine uptake with Lugol's iodine minimizes uptake of 131I MIBG by the thyroid.
The 10 patients with false-negative scans have brought attention to some technical points. First, cystic lesions may not be visualized with 131I MIBG. Second, lesions that cannot be seen with 131I MIBG may be visualized with 123I MIBG since a larger dose may be given. The short half-life and greater cost of 123I as compared to 131I make its routine use impractical. In difficult cases, however, it may prove to be the more sensitive agent.
Although 90% of adrenal pheochromocytomas may be visualized using CT scanning, this is not the case with extra-adrenal and metastatic lesions.
The success of 131I MIBG in localizing lesions not found by computed tomography proves it the better agent when metastatic lesions, small lesions, or extra-adrenal lesions are suspected. Pheochromocytomas as small as 0.5 cm in diameter have been visualized [2] .
The extremely high incidence of malignancy in this series of patients reflects the selectivity of patient referrals with malignant or occult pheochromocytomas because of the availability of MIBG as a scanning agent. There was a surprisingly high incidence of malignant extra-adrenal tumors found in this series (18 of 44 primary tumors). In most series, such tumors comprised no more than 10%. In a few cases, malignancy was first determined because of the extra-adrenal uptake of 131I MIBG in locations where chromaffin tissue should not normally be present. These lesions might have remained undetected for long periods of time without the use of this scanning agent.
The number of patients thus far treated with 131I MIBG for unresectable and metastatic lesions is small but the results are promising. To date, surgical ablation is the mainstay of treatment. Chemotherapeutic agents and radiation therapy have not been successful in arresting metastatic disease [8, 9] . Until now, treatment of metastases that were not surgically resectable has been palliative. Alphamethyl tyrosine, phenoxybenzamine, and in some cases beta adrenergic blocking drugs have been used. 131I MIBG is not blocked by phenoxybenzamine. Consequently, patients may continue this drug during treatment with 131I MIBG.
In conclusion, 131I MIBG scintigraphy is a safe, noninvasive diagnostic and therapeutic advance in the management of pheochromocytoma. It supplants other scintigraphic techniques for localization of pheochromocytomas and augments data obtained from computed tomography and angiography by providing functional as well as anatomic information.
R6sum6
De juin 1980 h ao0t 1983, 353 malades suspects d'6tre porteurs de ph6ochromocytomes ont 6t6 soumis h la scintigraphie ~ l'iode marqu6: I TM m6ta-iodobenzylguanidine (I TM MIBG). Des ph6ochro-mocytomes extra-surr6naliens ont 6t6 d6couverts chez 15 des 18 sujets suspects d'6tre porteurs de telles 16sions extra-surr6naliennes, ce qui fut constat6 lors de l'intervention qui d6montra que les surr6nales 6taient normales. Les autres m6thodes conventionnelles n'avaient pas permis de localiser ces tumeurs dans la majorit6 des cas. Neuf des ph6ochromocytomes extra-surr6naliens furent d6couverts dans la partie moyenne du m6diastin. Ce groupe de tumeurs implique la mise en oeuvre de techniques particuli6res en plus du scanner pour localiser la tumeur. Ces explorations compl6men-taires permettent de planifier l'intervention chirurgicale qui peut n6cessiter l'emploi d'une circulation extra-corporelle. Des ph6ochromocytomes extra-surr6naliens ont 6t6 d6couverts dans une famille qui ne prdsentait pas d'autres endocrinopathies. Les tumeurs chez 3 malades appartenant h 3 g6n6rations diff6rentes si6geaient hors de la surr6nale et int6ressaient la veine cave.
La scintigraphie h 1'I 131 marqu6 a permis de d6couvrir des mdtastases chez 40 malades porteurs d'un phdochromocytome malin, mais fut en d6faut dans 4 cas. Le diagnostic de ph6ochromocytome malin avec m6tastase fut port6 initialement chez 5 malades. La scintigraphie ne se solda par aucun faux positif mais 10,5% de faux n6gatifs furent constatds chez 95 malades o/1 la pr6sence d'un ph6ochromocytome fut prouv6e par les donn6es biologiques ou opdratoires.
Dix malades atteints de ph6ochromocytomes malins ont 6t6 trait6s par 1'1 TM marqu6. Cinq d'entre eux accus~rent une diminution de volume de la tumeur et des m6tastases et une diminution de la s6cr6tion des cat6cholamines. L'iode marqu6: p31 m6ta-iodobenzylguanidine permet de d6celer les ph6ochromocytomes qui 6chappent aux autres explorations. Le fair qu'il s'accumule 61ectivement au niveau de la tumeur permet de penser qu'il pourra jouer un r61e actif dans le traitement de l'affection.
Resumen
E1 diagn6stico de feocromocitoma con frecuencia es m~ts simple que establecer la localizaci6n anat6mica del tumor, lo cual es dificil, especialmente cuando el feocromocitoma es maligno, extraadrenal o bilateral. Aproximadamente el 10% de los feocromocitomas se origina en tejido cromafino ubicado en algt~n lugar entre la base del cr~ineo y la vejiga. La tomograffa computadorizada de tercera generaci6n es extremadamente precisa en la localizaci6n de lesiones intra-adrenales, pero no es muy t~til en la identificaci6n de feocromocitomas extra-adrenaleso metast~isicos. Hasta muy recientemente no existfa modalidad alguna capaz de proveer documentaci6n anat6mica y funcional del tumor con anterioridad a la intervenci6n quirtirgica. La sfntesis de la I TM metayodo-benzilguanidina (I TM MIBG) ha hecho posible obtener im~igenes scintigr~ificas de feocromocitomas y de tejido cromafino hiperpl~isico. Entre junio de 1980 y agosto de 1983, scintigramas con 1131 MIBG fueron realizados en 353 pacientes con sospecha de feocromocitoma. Se identificaron feocromocitomas extra-adrenales en 15 de 18 pacientes quienes ulteriormente demonstraron tenet tales tumores, con gl~indulas suprarrenales normales. Los estudios convencionales de localizaci6n, con frecuencia realizados en forma repetida habfan fallado en casi todos los casos. Nueve de los feocromocitomas extra-adrenales fueron hallados en el mediastino medio. Este grupo especial de tumores requiri6 estudios de localizaci6n adicionales con tomograffa computadorizada aumentada para el logro de la delineaci6n anat6mica especffica. Tales estudios complementarios hicieron posible la planeaci6n precisa de la excisi6n quirt~rgica, la cual necesit6 circulaci6n extracorp6rea en algunos casos. Feocromocitomas extraadrenales fueron identificados en una familia, la cuai no exhibi6 otras endocrinopatfas. Los tumores en 3 pacientes provenientes de 3 generaciones diferentes fueron todos de ubicaci6n peri-renal con compromiso de la vena cava.
Los estudios con 1 TM MIBG detectaron lesiones metast~isicas en 40 pacientes con feocromocitomas malignos. En s61o 4 pacientes las metfistasis no pudieron ser fftcilmente demostradas. E1 diagn6sti-co de feocromocitoma maligno y metasfftsico fue hecho en forma primaria por la scintigraffa en 5 pacientes. Los scintigramas con 1 TM MIBG no han dado resultados positivos falsos, en caso alguno, y han dado resultados negativos falsos en 10,5% de 95 pacientes con feocromocitoma comprobado por evidencia bioqufmica o por operaci6n.
Diez pacientes han sido tratados para feocromocitoma maligno con dosis terap6uticas de 1 TM MIBG. Cinco pacientes han manifestado respuesta objetiva con reducci6n del tamafio de las met~istasis o del tumor primario maligno con disminuci6n en la secreci6n de catecolaminas.
Este agente ha demostrado ser de gran valor en la detecci6n de feocromocitomas que han desafiado todos los otros m6todos de localizaci6n. La 1 TM MIBG se concentra en la mayorfa de los feocromocitomas malignos, y los resultados preliminares sugieren que habr~ de ser de gran utilidad en el tratamiento de esta enfermedad.
